TScan Therapeutics doubles authorized shares to 600M following shareholder approval

Filed May 22, 2026 · Period ending May 20, 2026 · ~1 min read

Key Changes

• high

  Shareholders approved doubling authorized common stock from 300 million to 600 million shares, effective May 20, 2026. This gives management significant capacity for future capital raises, acquisitions, or employee compensation.

  Item 5.03 verify on EDGAR →
• medium

  Certificate of Amendment to the company's Amended and Restated Certificate of Incorporation was filed with Delaware to implement the authorized share increase.

  Item 5.03 verify on EDGAR →
• low

  Katina Dorton and R. Keith Woods were elected as Class II directors for three-year terms ending in 2029, with strong shareholder support.

  Item 5.07 verify on EDGAR →